Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado

    Healthcare Companies Report Interim Data, Clinical Study Results, and
       Announcements - Research Report on Pfizer, Coronado Biosciences,
                    Spectranetics, Celsion, and Intercept

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, December 18, 2013

NEW YORK, December 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Coronado Biosciences, Inc. (NASDAQ: CNDO), The Spectranetics
Corporation (NASDAQ: SPNC), Celsion Corp. (NASDAQ: CLSN), and Intercept
Pharmaceuticals, Inc. (NASDAQ: ICPT). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Pfizer Inc. Research Report

On December 13, 2013, Pfizer Inc.'s (Pfizer) stock was flat, touching the
previous day close of $30.25 per share. Although, the Company's stock
reflected a decrease of 3.48% over the past three trading day period, compared
to the Dow Jones Industrial Average which went down by 1.36%, during the same
three day trading period. The Full Research Report on Pfizer Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

Coronado Biosciences, Inc. Research Report

On December 12, 2013, Coronado Biosciences, Inc. (Coronado Biosciences)
announced that Dr. Eric Hollander presented interim data from his pilot study
of oral TSO (Trichuris suis ova or CNDO-201). According to the Company, Dr.
Hollander is a Clinical Professor of Psychiatry and Behavioral Sciences at
Albert Einstein College of Medicine of Yeshiva University, and Director of the
Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center
and Einstein. The Company reported that during the study, 10 high-functioning
adult autism spectrum disorder patients who were able to give informed consent
to participate in the study, and who had a history of allergies and/or family
history of immune-inflammatory illness were treated for 12 weeks with either
TSO or placebo, followed by a 4-week washout phase and then 12 weeks of
placebo or TSO (with the TSO dosage used in the study at 2,500 ova given once
every two weeks). Additionally, the Company stated that the study is still
ongoing and final results are expected in the middle of 2014. The Full
Research Report on Coronado Biosciences, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/beea_CNDO

--

The Spectranetics Corporation Research Report

On December 13, 2013, The Spectranetics Corporation's (Spectranetics) stock
reflected an increase of 2.74% and closed the day at $24.79 per share. Over
the past three trading day period, the Company's stock went up by 2.23%,
compared to the Nasdaq composite which went down by 1.47% during the same
three day trading period. The Full Research Report on The Spectranetics
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/82e6_SPNC

--

Celsion Corp. Research Report

On December 13, 2013, Celsion Corp. (Celsion) announced the presentation of
the combined clinical study results from the Company's Phase I DIGNITY study
and the Duke University sponsored Phase I trial of ThermoDox ® plus
hyperthermia in Breast Cancer Recurrences at the Chest Wall (BCRCW) during
Poster Session #4, held on the same day at the 2013 San Antonio Breast Cancer
Conference, 7:30 a.m. to 9:00 a.m. (local time). According to the Company, the
poster titled "Novel Targeted Therapy for Breast Cancer Chest Wall Recurrence:
Low Temperature Liposomal Doxorubicin and Mild Local Hyperthermia" was
presented by Professor Hope S. Rugo, MD, from University of California, San
Francisco Comprehensive Cancer Center. The Full Research Report on Celsion
Corp. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e8ef_CLSN

--

Intercept Pharmaceuticals, Inc. Research Report

On December 13, 2013, Intercept Pharmaceuticals, Inc.'s (Intercept
Pharmaceuticals) stock went up by 4.38% as it closed the day at $62.92 per
share. The Company's stock went up by 6.18% over the past three trading day
period, compared to the Nasdaq composite which went down by 1.47% during the
same three trading day period. The Full Research Report on Intercept
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b477_ICPT

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.